DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for bone disease — screening already-approved drugs against its 42-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBone disease maps to a 42-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for bone disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphoglycerate dehydrogenase (PHGDH) — PHGDH is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1~{r}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6RJ3 · 1.42 Å · ligand 4-[(1~{R})-1-[(2-methyl-5-phenyl-pyrazol-3-yl)carbonylamino]ethyl]benzoic acid (K58). Experimental structure, not a prediction.
What the evidence adds up to
Disappearing bone disease, a rare condition of massive osteolysis, has no known cause and no treatment proven to arrest it. A 1987 abstract notes that histologically the involved bones show a nonmalignant proliferation of thin-walled vessels, but the mechanism of bone absorption remains unclear. Cases with extraosseous involvement carry a much poorer prognosis. No drug or intervention is mentioned as effective.
Paget's disease is described as the second most common bone disease in older adults. A 2004 article discusses its definition, incidence, aetiology, diagnosis through history, laboratory tests and imaging, and treatment options including pharmacologic management and prognosis. The abstract provides no specific drug names, response rates, or survival data.
Two later overviews, from 2011 and 2016, summarise progress in bone biology and signalling pathways. They note that mapping bone remodelling pathways has contributed to developing pharmaceuticals that can induce or suppress bone formation, and that potential new targets for therapeutic intervention in osteoporosis and arthritis are being identified. Neither abstract reports results from any clinical trial or gives concrete numbers for any drug's efficacy.
What is still missing for these bone diseases are completed, adequately powered clinical trials that test specific drugs against defined endpoints. For disappearing bone disease, even the basic mechanism is unclear, and no trial design has been established. For Paget's disease and osteoporosis, patient stratification and long-term outcome data remain incomplete. Funding for rare bone diseases is scarce.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Pediatric Orthopaedics · 1987 · 26 citations
Disappearing Bone Disease
AbstractDisappearing bone disease is a rare condition manifested by massive osteolysis. Its etiology is unknown. Histologically, involved bones show a nonmalignant proliferation of thin-walled vessels. The mechanism of bone absorption remains unclear. No treatment has proven effective in arresting the disease. Cases in which there is extraosseous involvement have a much poorer prognosis.
AbstractPaget's disease (PD) is the second most common bone disease in older adults, yet many clinicians are unfamiliar with it and may not consider it a diagnostic possibility. This article uses a case study to introduce the topic of Paget's disease. The definition, incidence, and etiology of PD is addressed. Normal bone physiology is defined in contrast to the pathophysiology of PD. Patient history, laboratory tests, and imaging studies are summarized with regard to the diagnosis of PD. Treatment options are discussed including pharmacologic management and prognosis. The article concludes with implications for nursing care of the patient with PD.
The South African Orthopaedic Journal (SAOJ) · 2016 · 0 citations · open access
Cell signalling and bone remodelling Part II: Developments in the pathogenesis and principles of management of selected skeletal disease states
AbstractMapping of the bone remodelling signalling pathways contributed significantly to the establishment of a scientific basis for the development of pharmaceuticals which have the potential to induce or suppress bone formation. Enhancing bone healing and the establishment of a pre-determined skeletal phenotype are now within reach of the medical profession. This manuscript provides practitioners with an overview of recent developments in the quest for uncovering the molecular mechanisms involved in the pathogenesis of selected bone disease states and the role these discoveries play in the future management of bone healing and skeletal health.
Novel Insights into Bone Remodeling: Closing in on New Ways to Fight Osteoporosis and Arthritis
AbstractThis overview presents progress in bone biology and highlighted potential new targets for therapeutic intervention. Included are the basic anatomy and physiology of bone; recent progress in the comprehension of the processes of bone formation and degradation; and the potential of novel therapeutic agents for bone disease in arthritis and osteoporosis.
Book reviewsRoentgen Diagnosis of Diseases of Bone. By EdeikenJ. and HodesP. J., pp. v + 701, 785 illus., 1967 (Edinburgh, E. & S. Livingstone Ltd., Baltimore, Williams & Wilkins Co.), £12 16<i>s</i>.
AbstractThis profusely illustrated book on bone disease is already established as one of the standard text-books on the subject. The format of the previous edition, which was edited by Pugh, is continued. The text and illustrations have been expanded and the quality of the X-ray reproductions have been much improved.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
